Breaking News
Get 40% Off 0
🎁 Free Gift Friday: Copy Legendary Investors' Portfolios in One Click Copy for Free
Close

Carna Biosciences Inc (4572)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
430.0 -6.0    -1.38%
14:00:29 - Closed. Currency in JPY ( Disclaimer )
Type:  Equity
Market:  Japan
ISIN:  JP3220550002 
  • Volume: 79,500
  • Bid/Ask: 430.0 / 433.0
  • Day's Range: 430.0 - 443.0
Carna Biosciences 430.0 -6.0 -1.38%

4572 Balance Sheet

 
Featured here, the Balance Sheet for Carna Biosciences Inc, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 4 period ending dates (either quarterly or annually).
AnnualQuarterly
Advanced Balance Sheet
Period Ending: 2023
31/12
2023
30/09
2023
30/06
2023
31/03
Total Current Assets 4191 4050 4407 4794
Cash and Short Term Investments 2889 3390 3684 4082
Cash - - - -
Cash & Equivalents 2889 3390 3684 4082
Short Term Investments - - - -
Total Receivables, Net 788 129 194 165
Accounts Receivables - Trade, Net 788 129 194 165
Total Inventory 140 139 139 136
Prepaid Expenses - - - -
Other Current Assets, Total 374 392 390 411
Total Assets 4349 4192 4565 4945
Property/Plant/Equipment, Total - Net 105 82 90 96
Property/Plant/Equipment, Total - Gross - - - -
Accumulated Depreciation, Total - - - -
Goodwill, Net - - - -
Intangibles, Net 1 1 1 1
Long Term Investments 51 57 65 53
Note Receivable - Long Term - - - -
Other Long Term Assets, Total 1 2 2 1
Other Assets, Total -274 402 335 382
Total Current Liabilities 375 277 325 389
Accounts Payable 1 - - 2
Payable/Accrued - - - -
Accrued Expenses - - - -
Notes Payable/Short Term Debt - - - -
Current Port. of LT Debt/Capital Leases 126 119 137 137
Other Current liabilities, Total 248 158 188 250
Total Liabilities 473 376 455 548
Total Long Term Debt 56 58 88 118
Long Term Debt 28 58 88 118
Capital Lease Obligations 28 - - -
Deferred Income Tax - - - -
Minority Interest - - - -
Other Liabilities, Total -106.4 -137.4 -166.4 -197.39
Total Equity 3876 3816 4110 4397
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 2076 2076 2052 2023
Additional Paid-In Capital 5827 5827 5803 5775
Retained Earnings (Accumulated Deficit) -4075 -4152 -3808 -3441
Treasury Stock - Common - - - -
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total 48 65 63 40
Total Liabilities & Shareholders' Equity 4349 4192 4565 4945
Total Common Shares Outstanding 17.14 17.14 17.09 16.99
Total Preferred Shares Outstanding - - - -
* In Millions of JPY (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

4572 Comments

Write your thoughts about Carna Biosciences Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email